Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP167781.RAXWigwwIfYUyibtZ8H0SVjplMG8Mi2jAv6-HOjHJ_R2Q130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP167781.RAXWigwwIfYUyibtZ8H0SVjplMG8Mi2jAv6-HOjHJ_R2Q130_assertion type Assertion NP167781.RAXWigwwIfYUyibtZ8H0SVjplMG8Mi2jAv6-HOjHJ_R2Q130_head.
- NP167781.RAXWigwwIfYUyibtZ8H0SVjplMG8Mi2jAv6-HOjHJ_R2Q130_assertion description "[In this study, we investigated the influence of the genetic polymorphisms GSTM1, GSTT1, and GSTP1 on treatment response in 94 Korean patients with de novo diffuse large B-cell lymphoma, who had received rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) as a front-line regimen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP167781.RAXWigwwIfYUyibtZ8H0SVjplMG8Mi2jAv6-HOjHJ_R2Q130_provenance.
- NP167781.RAXWigwwIfYUyibtZ8H0SVjplMG8Mi2jAv6-HOjHJ_R2Q130_assertion evidence source_evidence_literature NP167781.RAXWigwwIfYUyibtZ8H0SVjplMG8Mi2jAv6-HOjHJ_R2Q130_provenance.
- NP167781.RAXWigwwIfYUyibtZ8H0SVjplMG8Mi2jAv6-HOjHJ_R2Q130_assertion SIO_000772 20303013 NP167781.RAXWigwwIfYUyibtZ8H0SVjplMG8Mi2jAv6-HOjHJ_R2Q130_provenance.
- NP167781.RAXWigwwIfYUyibtZ8H0SVjplMG8Mi2jAv6-HOjHJ_R2Q130_assertion wasDerivedFrom gad-20150221 NP167781.RAXWigwwIfYUyibtZ8H0SVjplMG8Mi2jAv6-HOjHJ_R2Q130_provenance.
- NP167781.RAXWigwwIfYUyibtZ8H0SVjplMG8Mi2jAv6-HOjHJ_R2Q130_assertion wasGeneratedBy ECO_0000203 NP167781.RAXWigwwIfYUyibtZ8H0SVjplMG8Mi2jAv6-HOjHJ_R2Q130_provenance.